Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Short Interest Up 261.3% in November

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 1,550,000 shares, an increase of 261.3% from the November 15th total of 429,000 shares. Currently, 4.5% of the shares of the company are sold short. Based on an average trading volume of 5,300,000 shares, the short-interest ratio is presently 0.3 days.

Wall Street Analyst Weigh In

Separately, Benchmark reissued a “speculative buy” rating and set a $2.00 price objective on shares of Cardio Diagnostics in a report on Tuesday, August 27th.

Cardio Diagnostics Stock Up 16.0 %

Shares of CDIO stock traded up $0.19 during trading hours on Friday, hitting $1.39. The company’s stock had a trading volume of 6,139,174 shares, compared to its average volume of 2,085,695. Cardio Diagnostics has a twelve month low of $0.19 and a twelve month high of $3.56. The business has a fifty day moving average of $0.35 and a 200-day moving average of $0.42.

Cardio Diagnostics Company Profile

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.